← Every company
Crinetics Pharmaceuticals Inc Patents
What Crinetics Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
CRNX on carbonthat →Filings on file
61
Granted
3
Still pending
58
Filed under
2 names
61 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORSC07D 401/04, A61P 29/00, A61P 35/00, A61K 9/0019, A61K 9/0095, A61K 9/2054, A61K 9/4866, C07B2200/13Filed as Crinetics Pharmaceuticals, Inc.2026-04-06Jayachandra P. REDDY | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2026-03-25ALAN S. KRASNER | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2026-03-25ALEJANDRO AYALA | pending |
| PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2026-03-19SAMEER URGAONKAR | pending |
| PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOFC07D 413/04, A61K 31/553, C07D 413/14Filed as Crinetics Pharmaceuticals, Inc.2026-03-19Sameer URGAONKAR | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEFiled as CRINETICS PHARMACEUTICALS, INC.2026-03-16ALAN S. KRASNER | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROMEFiled as CRINETICS PHARMACEUTICALS, INC.2026-03-02ALAN S. KRASNER | pending |
| PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2026-02-18Sameer URGAONKAR | pending |
| NONPEPTIDE GLP-1 AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2026-02-12JOSEPH PONTILLO | pending |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2026-02-12JIAN ZHAO | pending |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2026-01-23Jian ZHAO | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2026-01-16Alejandro AYALA | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2026-01-09Alan S. KRASNER | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-12-23Alejandro Ayala | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-12-19Alan S. KRASNER | pending |
| NONPEPTIDE GLP-1 AGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2025-12-19Joseph PONTILLO | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAA61K 31/496, A61P 17/10, A61P 5/08, A61P 15/02, A61P 15/00, A61P 5/28, A61K 31/573, A61K2300/00Filed as CRINETICS PHARMACEUTICALS, INC.2025-11-17Alejandro AYALA | pending |
| MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOFC07D 401/14, Y02A 50/30, A61P 5/00, C07D 453/02Filed as Crinetics Pharmaceuticals, Inc.2025-10-29Sangdon HAN | pending |
| SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOFC07D 471/10, C07D 471/20, A61P 5/38Filed as Crinetics Pharmaceuticals, Inc.2025-10-14Sangdon HAN | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROMEFiled as CRINETICS PHARMACEUTICALS, INC.2025-10-13Alan S. KRASNER | pending |
| THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOFA61K 31/4375, A61K 31/538, C07D 401/04, A61P 5/14, A61K 31/4709, A61K 31/497, C07D 401/14, C07D 405/04, C07D 405/14, C07D 413/04, C07D 413/14, C07D 417/04, C07D 417/14, C07D 455/04, C07D 471/04, C07D 487/04Filed as CRINETICS PHARMACEUTICALS, INC.2025-10-10Collin REGAN | pending |
| THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2025-10-10COLLIN REGAN | pending |
| MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF ACTH-DEPENDENT CUSHING'S SYNDROMEA61K 31/496, A61P 5/38, A61P 5/08, A61P 5/00, C07D 471/18Filed as CRINETICS PHARMACEUTICALS, INC.2025-10-02Peter TRAINER | pending |
| THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2025-08-11Collin REGAN | pending |
| MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOFC07D 241/04, C07D 401/14, A61P 5/00, C07D 295/04, C07D 401/10, C07D 405/14, C07D 407/14, C07D 409/14, C07D 413/14, C07D 453/02Filed as Crinetics Pharmaceuticals, Inc.2025-07-28Sangdon HAN | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEFiled as CRINETICS PHARMACEUTICALS, INC.2025-07-10Alan S. KRASNER | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-07-02Alan S. KRASNER | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-07-02Alejandro AYALA | pending |
| SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2025-06-09JIAN ZHAO | pending |
| SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOFA61K 47/65, A61K 47/545, A61K 47/542, A61K 47/54, A61K 47/549, A61P 35/00, C07K 5/06026, C07K 5/06052, C07K 5/06086, C07K 5/0806, C07K 5/081, C07K 5/0819, C07K 5/0821, C07K 7/02, C07K 9/003Filed as Crinetics Pharmaceuticals, Inc.2025-06-09Jian ZHAO | pending |
| SOMATOSTATIN MODULATORS AND USES THEREOFC07D 401/04, A61P 27/02, A61P 5/08, A61P 25/28, A61P 43/00, A61P 25/04, A61P 13/12, A61P 11/00, A61P 25/00, A61P 29/00, A61P 35/00, A61K 9/20, A61K 9/48, A61K 31/454, A61K 31/4709, A61K 31/4725, A61K 31/502, A61K 31/5377, A61K 31/5383, A61K 31/553, C07D 401/14, C07D 405/14, C07D 413/14, C07D 471/04, C07D 498/04, C07D 519/00Filed as Crinetics Pharmaceuticals, Inc.2025-04-25Jian ZHAO | pending |
| SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2025-04-11Jian ZHAO | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-03-26Alejandro Ayala | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2025-03-26Alan S. KRASNER | pending |
| PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2025-03-21Sameer URGAONKAR | pending |
| MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASEA61P 5/08, A61K 31/496, A61P 5/38, A61K 9/0053, A61K 31/573Filed as Crinetics Pharmaceuticals, Inc.2025-03-18Christine FERRARA-COOK | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEFiled as CRINETICS PHARMACEUTICALS, INC.2025-03-17Alan S. KRASNER | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROMEFiled as CRINETICS PHARMACEUTICALS, INC.2025-03-03Alan S. KRASNER | pending |
| NONPEPTIDE GLP-1 AGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2025-02-14Joseph PONTILLO | pending |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2025-02-14Jian ZHAO | pending |
| COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTA61K 31/4709, A61P 1/16, A61K 9/0053, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/2813, A61K 9/2866, A61K 31/381Filed as CRINETICS PHARMACEUTICALS, INC.2024-12-18Lance GOULET | pending |
| SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-11-20SUN HEE KIM | pending |
| SOMATOSTATIN MODULATORS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2024-11-19Jian ZHAO | pending |
| THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-10-11Collin REGAN | pending |
| SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-09-25SUN HEE KIM | pending |
| NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOFC07D 401/04, A61P 5/48, A61P 3/08, A61P 3/10, A61K 31/4439, A61K 31/444, C07D 401/14Filed as Crinetics Pharmaceuticals, Inc.2024-09-03Jian ZHAO | 12600709 |
| SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-07-30Sun Hee KIM | pending |
| SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-07-11SUN HEE KIM | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROMEA61K 31/4709, A61P 1/12, A61P 5/00, A61P 5/06, A61P 35/00, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/2059, A61K 9/28, A61K 9/4825, A61K 9/485, A61K 9/4858, A61K 9/4866Filed as Crinetics Pharmaceuticals, Inc.2024-07-10Alan S. KRASNER | pending |
| USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEA61K 31/4709, A61P 43/00, A61P 5/06, A61P 5/24, A61B 5/14532, A61K 9/0053, A61K 9/146, A61K 9/1635, A61K 9/1652, A61K 9/2027, A61K 9/2054, A61K 31/48, A61K 45/06, A61K2300/00, G01N 33/66, G01N 33/74, G01N2333/65, G01N2800/52Filed as Crinetics Pharmaceuticals, Inc.2024-07-02Ajay MADAN | pending |
| SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOFFiled as CRINETICS PHARMACEUTICALS, INC.2024-06-11Jian ZHAO | pending |
| SOMATOSTATIN MODULATORS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2024-06-06Jian ZHAO | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2024-05-16ALEJANDRO AYALA | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIAFiled as CRINETICS PHARMACEUTICALS, INC.2024-04-09Alejandro AYALA | pending |
| MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF ACTH-DEPENDENT CUSHING'S SYNDROMEFiled as CRINETICS PHARMACEUTICALS, INC.2024-04-03PETER TRAINER | pending |
| COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTFiled as CRINETICS PHARMACEUTICALS, INC.2024-03-25LANCE GOULET | pending |
| COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTA61K 31/4709, A61P 1/16, A61K 9/0053, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/2813, A61K 9/2866, A61K 31/381Filed as CRINETICS PHARMACEUTICALS, INC.2024-03-25Lance GOULET | 12208092 |
| NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOFFiled as Crinetics Pharmaceuticals, Inc.2024-03-21Jian ZHAO | pending |
| FORMULATIONS OF A SOMATOSTATIN MODULATORA61K 9/1611, A61K 9/1652, A61K 31/4709, A61P 5/08, A61K 9/0053, A61K 9/1617, A61K 9/1623, A61K 9/1635, A61K 9/1694, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/4825, A61K 45/06Filed as Crinetics Pharmaceuticals, Inc.2024-03-08Gerald BURKE | pending |
| PROCESS OF MAKING SOMATOSTATIN MODULATORSA61K 31/4709, C07D 401/04, A61P 35/00, C07B2200/13, C07D 498/04, C07F 5/02Filed as Crinetics Pharmaceuticals, Inc.2024-02-26Jayachandra P. REDDY | pending |
| SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOFA61K 47/545, C07D 401/14, C07H 15/203, C07K 5/0205, A61K 47/65, A61K 47/551, A61P 35/00, A61K 9/0019, A61K 9/08, A61K 51/0455, A61K 51/0491, A61K 51/0497, C07D 405/14, C07D 491/22, C07D 498/04, C07D 498/18, C07K 5/0202, C07K 5/06052, C07K 5/081, C07K 5/0819, C07K 5/1008, C07K 5/1021Filed as Crinetics Pharmaceuticals, Inc.2024-02-06Jian ZHAO | 12134610 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.